Related Experiment Videos
Human hybridomas from patients with malignant disease
British Journal of Cancer
|January 1, 1983
Summary
Researchers fused patient lymphocytes with myeloma cells to create hybridomas. Twelve of these hybridomas produced antibodies with anti-tumor binding activity, offering potential for cancer research.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- Hybridoma technology is crucial for monoclonal antibody production.
- Identifying novel antibodies against cancer targets is a key challenge in oncology.
Purpose of the Study:
- To generate hybridomas from lymphocytes of cancer patients.
- To screen for hybridoma-derived antibodies with anti-tumor activity.
Main Methods:
- Lymphocytes from 180 cancer patients were fused with the human myeloma cell line LON-LICR-HMy2/CAM1.
- 162 hybridomas were successfully generated and characterized.
- Flow cytometry was used to analyze DNA content and surface markers.
- Hybridoma supernatants were screened for immunoglobulin (Ig) chains and anti-tumor binding activity.
Main Results:
- All fusion products exhibited B lymphocyte markers.
- Hybridoma cells showed a stable increase in DNA content.
- New immunoglobulin chains were detected in some hybridoma supernatants.
- Twelve hybridoma supernatants demonstrated specific anti-tumor binding activity.
Conclusions:
- Hybridoma technology can be successfully applied to generate antibody-producing cell lines from cancer patients.
- The identified hybridomas producing anti-tumor antibodies represent a valuable resource for further development in cancer immunotherapy and diagnostics.